Now showing items 1-2 of 2

    • Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21. 

      Müller, LME; Holmes, M; Michael, JL; Scott, GB; West, EJ; Scott, KJ; Parrish, C; Hall, K; Stäble, S; Jennings, VA; Cullen, M; McConnell, S; Langton, C; Tidswell, EL; Shafren, D; Samson, A; Harrington, KJ; Pandha, H; Ralph, C; Kelly, RJ; Cook, G; Melcher, AA; Errington-Mais, F (2019-07)
      BACKGROUND:The oncolytic virus, coxsackievirus A21 (CVA21), has shown promise as a single agent in several clinical trials and is now being tested in combination with immune checkpoint blockade. Combination therapies offer ...
    • Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition. 

      Jennings, VA; Scott, GB; Rose, AMS; Scott, KJ; Migneco, G; Keller, B; Reilly, K; Donnelly, O; Peach, H; Dewar, D; Harrington, KJ; Pandha, H; Samson, A; Vile, RG; Melcher, AA; Errington-Mais, F (2019-06)
      A clinical oncolytic herpes simplex virus (HSV) encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), talimogene laherparepvec, causes regression of injected and non-injected melanoma lesions in patients and ...